Related Experiment Video
Updated: Jan 14, 2026
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
Published on: July 7, 2017
Real-life impact of anti-IL5 therapy on exacerbation types in patients with obstructive lung disease
Lowie E G W Vanfleteren1,2, Delphine Vauterin3, Lies Lahousse4,5
1Department of Internal Medicine and Clinical Nutrition, University of Gothenburg Sahlgrenska Academy, Gothenburg, Sweden.
Background:
While anti-interleukin (IL) 5 therapy has been shown to be efficacious to reduce exacerbation rates (ERs) in patients with severe eosinophilic asthma and might also benefit patients with coexisting chronic obstructive pulmonary disease (COPD), it is unknown whether anti-IL5 therapy reduces all types of exacerbations in heterogeneous (smoking) real-life patients.
Methods:
Adults initiating mepolizumab or benralizumab between 2017 and 2019 were identified in Belgian nationwide data. The ER in the year before anti-IL5 therapy initiation was compared to the year after. Exacerbations were classified as severe (hospitalised) exacerbations or moderate (outpatient) exacerbations treated with antibiotics, oral corticosteroids (OCS) or the combination.
Results:
Among 807 patients initiating anti-IL5 therapy, severe ER was 40±4 exacerbations per 100 patient years pretreatment versus 17±3 post-treatment initiation (p<0.001, relative risk reduction (RRR) -56%, number needed to treat (NNT)=4) and significantly reduced both in patients without COPD (n=616, ERpre=15±2, ERpost=6±1, p<0.001, NNT=11) as with coexisting COPD (n=191, ERpre=119±12, ERpost=53±9, p<0.001, NNT=2). For moderate exacerbations, ERs were significantly reduced for all types of exacerbations in both patients with or without COPD, except for OCS only-treated exacerbations in patients with coexisting COPD (p=0.288). Current smoking reduced anti-IL5 effectiveness on OCS-treated exacerbations (NNT >1), although current smokers with coexisting COPD still had a great reduction in hospitalisations (ERpre=152±23, ER post=55±18, p<0.001, NNT=1, RRR=-64%).
Conclusions:
In this nationwide cohort study, treatment targeting eosinophilic inflammation was significantly associated with reduced moderate and severe exacerbations, with seemingly less impact on corticosteroid-treated exacerbations in (current smoking) patients with coexisting COPD, but still a large number of hospitalisations were prevented.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...